EUCTR2004-000315-26-IT进行中（未招募）不适用
First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. An Expanded Access Program.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- ROCHE
- 入组人数
- 1,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. An Expanded Access Program. - First BEATMetastatic cancer of the colon or rectum.EUCTR2004-000315-26-SKF.Hoffmann-La Roche Ltd.2,000
进行中（未招募）
不适用
First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. An Expanded Access Program. - First BEATMetastatic cancer of the colon or rectum.EUCTR2004-000315-26-HUF. Hoffmann-La Roche Ltd.2,000
进行中（未招募）
1 期
First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum.Metastatic cancer of the colon or rectum.EUCTR2004-000315-26-ESF. Hoffmann-La Roche Ltd.2,000
已完成
不适用
Bevacizumab and CHOP (A-CHOP) in Combination for Patients With Peripheral T-Cell or Natural Killer Cell NeoplasmsPER-015-08EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),
已完成
3 期
A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum.Colorectal CancerNCT01169558Hoffmann-La Roche168